PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs)

Medical Oncology
Jian LiLin Shen

Abstract

Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) pathway activation may be related to imatinib resistance; however, no study has focused on whether signal conduction of this pathway will change after imatinib resistance. A total of 111 GIST samples from 91 patients were used in this study, including 20 pairs of samples before and after imatinib treatment. Immunohistochemistry was performed on tissue for p-KIT (phospho-KIT), PTEN (phosphatase and tensin homolog deleted on chromosome ten), PI3K, phospho-AKT (p-AKT), phospho-4EBP1 (p-4EBP1) and phospho-S6 (p-S6RP). The activation of AKT/mTOR was significantly higher in imatinib secondary resistant GIST (53.1 %) than in imatinib-sensitive (27.1 %) and primary resistant GIST (33.3 %) (P = 0.049). In the analysis of 20 pairs of samples, comparing pre-imatinib GIST with on-treatment ones, the PI3K status was changed from inactivated to activated in four cases each in eight patients with effective imatinib and 12 patients whose secondary resistance happened, respectively. AKT/mTOR status was inactivated in pre-imatinib and on-treatment samples in eight patients with effective imatinib; however, the status of six patients was changed from inactivated to ...Continue Reading

References

Jul 3, 2002·Nature Reviews. Cancer·Igor Vivanco, Charles L Sawyers
Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
Aug 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Ferdinand RossiPeter Besmer
Sep 7, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael C HeinrichJonathan A Fletcher
May 22, 2007·Lancet·Brian P RubinChristopher L Corless
Jun 14, 2008·Proceedings of the National Academy of Sciences of the United States of America·Chi TarnAndrew K Godwin
Aug 2, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F PerroneS Pilotti
Oct 1, 2008·Journal of Gastroenterology and Hepatology·Nayoung KimIn Sung Song
Oct 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael C HeinrichGeorge D Demetri
Dec 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ann W GramzaMichael C Heinrich
Jan 1, 2010·Journal of Cancer Research and Clinical Oncology·Chun-Meng WangYing-Qiang Shi
May 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P SchöffskiG D Demetri
Feb 18, 2011·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·Zoltán SápiGyörgy Bodoky
May 25, 2011·Journal of Translational Medicine·Alessandra MaledduGuido Biasco

❮ Previous
Next ❯

Citations

Dec 17, 2016·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Rashmi R Shah
May 2, 2018·Personalized Medicine·Souvik GhatakNachimuthu Senthil Kumar
Jun 6, 2019·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·Jingyi YanWei Chen
Aug 17, 2019·Cancers·Sioletic Stefano, Scambia Giovanni
Oct 2, 2020·Applied Immunohistochemistry & Molecular Morphology : AIMM·Si WangYang Liu
Jul 3, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Phillip ZookLori Rink
Dec 16, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Fangxi XueFeng Tian

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Cardiac Conduction System

The cardiac conduction system is a specialized tract of myocardial cells responsible for maintaining normal cardiac rhythm. Discover the latest research on the cardiac conduction system here.